Effectiveness and safety of Eribulin in metastatic breast cancer

Background: Breast cancer is the most common cancer in women worldwide. Eribulin monotherapy is approved for the treatment of patients with locally advanced or metastatic breast cancer with disease progression after at least one chemotherapy regimen for advanced disease. We assessed the effectiveness, referred to as Progression-Free Survival (PFS) (primary objective) and safety, referred to as adverse reactions (secondary objective) of using eribulin in the treatment of metastatic breast cancer in our center. Method: Retrospective observational study of all patients diagnosed with metastatic breast cancer and treated with eribulin was used. Demographic variables (sex, age, body surface) and clinics (diagnosis, type of receptors: Her-2 receptors or/and Hormone Receptors (HR): estrogen and progesterone, Preliminary Therapeutic Lines (PTL), managed cycles, dose reductions and/or suspensions and reason, start and end dates of treatment, disease progression and resulted in death if necessary) were collected. Results: PFS obtained was 7.33 months (4.41-10.26). The most common adverse reactions collected in the 19 women included (No. = 19) were: alopecia in 15 patients (78.95%), neurotoxicity grade 1 and grade 2 in 13 patients (68.42%), asthenia in 12 patients (63.16%), gastrointestinal toxicity in seven patients (36.84%) and neutropenia in eight patients (42.11 %). Conclusions: The median PFS was superior to that obtained in the reference EMBRACE study, but due to our sample size was limited, it is necessary to extend the study to confirm the efficacy and safety. Adverse effects detected were similar to those described in the literature, highlighting alopecia in almost all patients